President Trump's dismissal of two FTC Democratic members raises concerns about the future of the agency's lawsuit against major pharmacy middlemen. The lawsuit accuses them of steering patients to high-cost insulin products for profit, with discovery scheduled to conclude in June.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing